Research ArticleCancer

Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms

See allHide authors and affiliations

Science Translational Medicine  21 Feb 2018:
Vol. 10, Issue 429, eaam7729
DOI: 10.1126/scitranslmed.aam7729

Cancers JAK up an immune checkpoint

Myeloproliferative neoplasms, a group of hematologic cancers, are associated with mutations activating the JAK2 oncogene. JAK2 is located on chromosome 9, in the vicinity of the immunosuppressive PD-L1 gene, and Prestipino et al. discovered that myeloproliferative cancers with overactive JAK2 generally have increased PD-L1 as well. Although PD-L1 helps cancers evade the immune system, immune checkpoint inhibitors developed in recent years provide a way to block its function and turn PD-L1 expression into a therapeutic vulnerability for the tumors, as the authors demonstrate in this study.

View Full Text

Stay Connected to Science Translational Medicine